Dermatologic Manifestations and Pulmonary Involvement in Two Patients with Hypereosinophilic Syndrome - A Case Series

Mehrdad Payandeh¹, Afshin Karami^2, , Noorodin Karami³, Mehrnoosh Aeinfar¹, Fatemeh Feizi², Amir Yami², Akram Sourni⁴ and Hedieh Heidary⁴

¹Department of Hematology and Medical Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran

²Department of Hematology, Shahid Beheshti University of Medical Sciences, Tehran, Iran

³Department of Genetics, Shahid Sadoughi University of Medical Science, Yazd, Iran

⁴Department of Nursing, Kermanshah University of Medical Sciences, Kermanshah, Iran

Cite this paper:
Mehrdad Payandeh, Afshin Karami, Noorodin Karami, Mehrnoosh Aeinfar, Fatemeh Feizi, Amir Yami, Akram Sourni and Hedieh Heidary. Dermatologic Manifestations and Pulmonary Involvement in Two Patients with Hypereosinophilic Syndrome - A Case Series. American Journal of Cancer Prevention. 2018; 6(2):20-23. doi: 10.12691/ajcp-6-2-1

Abstract

Hypereosinophilic syndrome is a group of disorders described by excessive production of eosinophils, their infiltration and the release of mediators that cause damage to multiple organs. Two patients of 67 and 38 years old, were referred to the clinic of Hematology and Oncology, Kermanshah, Iran, in 2016 and 2017, respectively. In the first case, there was no suspicious item in the patient's medical records and his most prominent features were pulmonary emphysema, and hypopigmented lesions, while in the second case, in addition to having a history of asthma, lesions of eczema were also seen. Hence, according to these characteristics and the results of the tests performed, our differential diagnosis was the Hypereosinophilic syndrome. We started the treatment with two types of drugs, Imatinib and Prednisolone. The treatment of patients is still ongoing and their condition was relatively promising.

Keywords:
hypereosinophilic syndrome pulmonary emphysema eczema imatinib

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

References:

[1]	Nayak VH, Engin NY, Burns JJ, Ameta P. Hypereosinophilic Syndrome With Eosinophilic Gastritis. Global Pediatric Health. 2017; 4: 2333794X17705239.
[2]	Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine. 1975; 54(1): 1-27.
[3]	Valent P, Klion AD, Horny H-P, Roufosse F, Gotlib J, Weller PF, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. Journal of Allergy and Clinical Immunology. 2012; 130(3): 607-12. e9.
[4]	Roufosse FE, Goldman M, Cogan E. Hypereosinophilic syndromes. Orphanet journal of rare diseases. 2007; 2(1): 37.
[5]	Gotlib J. World Health Organization‐defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management. American journal of hematology. 2014; 89(3): 325-37.
[6]	Karnak D, Kayacan O, Beder S, Delibalta M. Hypereosinophilic syndrome with pulmonary and cardiac involvement in a patient with asthma. Canadian Medical Association Journal. 2003; 168(2): 172-5.
[7]	Park J-h, Lee W-s, Park SJ, Yoo W-h. Hypereosinophilic Syndrome Associated with the Onset of Rheumatoid Arthritis: A Case Report. Journal of Rheumatic Diseases (구 대한류마티스학회지). 2017; 24(3): 165-8.
[8]	Ghersin I, Elias N, Slobodin G, Odeh M. Exacerbation of hypereosinophilic syndrome with pulmonary involvement in two consecutive pregnancies: a case report and review of the literature. International Journal of Research in Medical Sciences. 2017; 2(4): 1774-6.
[9]	Bain BJ. Hypereosinophilia. Current opinion in hematology. 2000; 7(1): 21-5.
[10]	Shehwaro N, Langlois AL, Gueutin V, Izzedine H. Renal involvement in idiopathic hypereosinophic syndrome. Clinical kidney journal. 2013; 6(3): 272-6.
[11]	Klion AD. How I treat hypereosinophilic syndromes. Blood. 2015; 126(9): 1069-77.
[12]	Gotlib J, Cools J, Malone JM, Schrier SL, Gilliland DG, Coutré SE. The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood. 2004; 103(8): 2879-91.
[13]	Bosslet GT, Knox KS, Noor A. Severe idiopathic hypereosinophilic syndrome. Respiratory Medicine CME. 2008; 1(2): 100-2.
[14]	Levin HR, Gelfand M. Method and apparatus for treatment of congestive heart failure by improving perfusion of the kidney. Google Patents; 2003.
[15]	Leiferman KM, Gleich GJ. Hypereosinophilic syndrome: case presentation and update. Journal of allergy and clinical immunology. 2004; 113(1): 50-8.
[16]	Leiferman KM, Gleich GJ, Peters MS. Dermatologic manifestations of the hypereosinophilic syndromes. Immunology and allergy clinics of North America. 2007; 27(3): 415-41.
[17]	Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. New England Journal of Medicine. 2003; 348(13): 1201-14.
[18]	Pardanani A, Ketterling RP, Li C-Y, Patnaik M, Wolanskyj A, Elliott M, et al. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leukemia research. 2006; 30(8): 965-70.
[19]	Martinelli G, Malagola M, Ottaviani E, Rosti G, Trabacchi E, Baccarani M. Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome. Haematologica. 2004; 89(2): 236-7.
[20]	Fauci AS, Harley JB, Roberts WC, Ferrans VJ, Gralnick HR, Bjornson BH. The Idiopathic Hypereosinophilic Syndrome Clinical, Pathophysiologic, and Therapeutic Considerations. Annals of Internal Medicine. 1982; 97(1): 78-92.